Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Vildagliptin). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Vilagli Tablet is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Recommended dosing for Vildagliptin is 50 mg or 100 mg once daily as monotherapy. For dual combination therapy with Metformin or a Thiazolidinedione, the dose is 50 mg twice daily, taken in the morning and evening. When combined with a Sulphonylurea, 50 mg is given once daily in the morning. Vildagliptin can be taken with or without food. No dose adjustment is needed for elderly patients or those with mild renal impairment. Pediatric use: Vildagliptin is not recommended for patients under 18 years of age.
Side Effects
Most people experience only mild, short-lived side effects that do not require stopping treatment. Liver problems are seen rarely. Clinical trials lasting up to and beyond 2 years revealed no additional safety concerns or unexpected risks with the use of Vildagil.
Cautions & Contraindications
Warnings & Precautions
Caution should be exercised in patients aged 75 years and older due to limited clinical experience. It is recommended that LFTs are monitored prior to initiation of Vildagil, at three-monthly intervals in the first year and periodically thereafter. If transaminase levels are increased, patients should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality returns to normal. If AST or ALT persists at 3xULN, Vildagil treatment should be stopped. Patients who develop jaundice or other signs of liver dysfunction should discontinue Vildagil. Following the withdrawal of treatment with Vildagil and LFT normalization, treatment with Vildagil should not be reinitiated. Due to limited clinical experience, use with caution in patients with congestive heart failure of New York Heart Association (NYHA) functional class I-II, and do not use in patients with NYHA functional class III IV.
Contraindications
Vildagliptin is contraindicated in patients with: Hypersensitivity to the active substance or to any of the excipients Patients with moderate to severe renalImpairment Patients with Hepatic Impairment: patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotrasferase (AST) >3 times the upper limit of normal (ULN). Patients with type 1 diabetes